Loading...

Mologen

DB:MGNK
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MGNK
DB
€23M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases. The last earnings update was 168 days ago. More info.


Add to Portfolio Compare Print
  • Mologen has significant price volatility in the past 3 months.
MGNK Share Price and Events
7 Day Returns
-13.1%
DB:MGNK
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-43.5%
DB:MGNK
-5.6%
DE Biotechs
-4.5%
DE Market
MGNK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Mologen (MGNK) -13.1% 36.2% 32.6% -43.5% -83% -94.6%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • MGNK underperformed the Biotechs industry which returned -5.6% over the past year.
  • MGNK underperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
MGNK
Industry
5yr Volatility vs Market

MGNK Value

 Is Mologen undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Mologen to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Mologen.

DB:MGNK Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 9.2%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:MGNK
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 30%) (30.51%))
1.511
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.51
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.511 * 5.96%)
9.24%

Discounted Cash Flow Calculation for DB:MGNK using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Mologen is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:MGNK DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 9.24%)
2019 -13.00 Analyst x1 -11.90
2020 37.00 Analyst x1 31.01
2021 65.08 Est @ 75.9% 49.93
2022 99.70 Est @ 53.2% 70.03
2023 136.90 Est @ 37.31% 88.02
2024 172.74 Est @ 26.18% 101.68
2025 204.52 Est @ 18.4% 110.20
2026 231.00 Est @ 12.95% 113.95
2027 252.09 Est @ 9.13% 113.84
2028 268.38 Est @ 6.46% 110.95
Present value of next 10 years cash flows €777.70
DB:MGNK DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €268.38 × (1 + 0.23%) ÷ (9.24% – 0.23%)
€2,986.32
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €2,986.32 ÷ (1 + 9.24%)10
€1,234.53
DB:MGNK Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €777.70 + €1,234.53
€2,012.23
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €2,012.23 / 7.54
€266.97
DB:MGNK Discount to Share Price
Calculation Result
Value per share (EUR) From above. €266.97
Current discount Discount to share price of €3.05
= -1 x (€3.05 - €266.97) / €266.97
98.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Mologen is available for.
Intrinsic value
>50%
Share price is €3.05 vs Future cash flow value of €266.97
Current Discount Checks
For Mologen to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Mologen's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Mologen's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Mologen's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Mologen's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MGNK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-09-30) in EUR €-1.90
DB:MGNK Share Price ** DB (2019-04-24) in EUR €3.05
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Mologen.

DB:MGNK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:MGNK Share Price ÷ EPS (both in EUR)

= 3.05 ÷ -1.90

-1.61x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mologen is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Mologen is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Mologen's expected growth come at a high price?
Raw Data
DB:MGNK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.61x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
94.3%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Mologen, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Mologen's assets?
Raw Data
DB:MGNK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-09-30) in EUR €-1.01
DB:MGNK Share Price * DB (2019-04-24) in EUR €3.05
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:MGNK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:MGNK Share Price ÷ Book Value per Share (both in EUR)

= 3.05 ÷ -1.01

-3.02x

* Primary Listing of Mologen.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Mologen has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess Mologen's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Mologen has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MGNK Future Performance

 How is Mologen expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
94.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Mologen expected to grow at an attractive rate?
  • Mologen's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Mologen's earnings growth is expected to exceed the Germany market average.
  • Mologen's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:MGNK Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MGNK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 94.3%
DB:MGNK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 20.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MGNK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MGNK Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 20 1
2022-12-31 3 1
2021-12-31 0 1
2020-12-31 50 38 37 1
2019-12-31 0 -13 -15 2
2018-12-31 3 -15 -14 2
DB:MGNK Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-09-30 4 -14 -14
2018-06-30 4 -14 -13
2018-03-31 3 -18 -15
2017-12-31 0 -19 -19
2017-09-30 0 -21 -22
2017-06-30 0 -21 -22
2017-03-31 0 -21 -22
2016-12-31 0 -19 -21
2016-09-30 0 -20 -22
2016-06-30 0 -20 -23
2016-03-31 0 -17 -22
2015-12-31 0 -15 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Mologen's earnings are expected to grow significantly at over 20% yearly.
  • Mologen's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MGNK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Mologen Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MGNK Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 3.03 3.03 3.03 1.00
2019-12-31 -1.45 -1.06 -1.84 2.00
2018-12-31 -1.53 -1.53 -1.53 2.00
DB:MGNK Past Financials Data
Date (Data in EUR Millions) EPS *
2018-09-30 -1.90
2018-06-30 -1.89
2018-03-31 -2.06
2017-12-31 -2.82
2017-09-30 -3.21
2017-06-30 -3.60
2017-03-31 -3.91
2016-12-31 -4.25
2016-09-30 -4.74
2016-06-30 -5.18
2016-03-31 -4.91
2015-12-31 -4.93

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Mologen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Mologen's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Mologen has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MGNK Past Performance

  How has Mologen performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Mologen's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Mologen does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Mologen's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Mologen's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Mologen's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Mologen Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MGNK Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-09-30 3.97 -13.60 5.44
2018-06-30 3.73 -13.32 5.42
2018-03-31 3.03 -14.91 5.46
2017-12-31 0.06 -19.28 5.33
2017-09-30 0.09 -21.60 5.30
2017-06-30 0.11 -21.90 5.18
2017-03-31 0.11 -21.71 5.60
2016-12-31 0.07 -21.00 5.67
2016-09-30 0.03 -21.59 5.78
2016-06-30 0.00 -23.48 5.77
2016-03-31 0.02 -21.87 5.25
2015-12-31 0.04 -20.54 5.28
2015-09-30 0.04 -17.01 5.22
2015-06-30 0.04 -16.10 5.29
2015-03-31 0.02 -16.19 5.20
2014-12-31 0.01 -17.08 5.32
2014-09-30 0.02 -17.36 5.26
2014-06-30 0.06 -14.43 5.10
2014-03-31 0.21 -12.71 5.04
2013-12-31 0.23 -10.83 4.57
2013-09-30 0.19 -9.09 4.32
2013-06-30 0.18 -8.71 4.21
2013-03-31 0.23 -8.37 3.87
2012-12-31 0.32 -7.99 3.70
2012-09-30 0.60 -8.15 3.51
2012-06-30 0.70 -7.86 3.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Mologen has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Mologen has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Mologen improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Mologen's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Mologen has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MGNK Health

 How is Mologen's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Mologen's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Mologen's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Mologen's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Mologen's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Mologen has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Mologen Company Filings, last reported 6 months ago.

DB:MGNK Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-09-30 -7.60 7.01 4.17
2018-06-30 -3.28 5.50 6.21
2018-03-31 0.16 5.46 8.28
2017-12-31 -4.87 5.43 6.52
2017-09-30 -2.19 6.56 9.81
2017-06-30 1.82 6.61 14.15
2017-03-31 6.74 7.09 19.44
2016-12-31 11.84 2.12 20.52
2016-09-30 4.91 0.02 10.19
2016-06-30 9.75 0.02 15.33
2016-03-31 15.04 0.01 20.12
2015-12-31 19.50 0.01 24.59
2015-09-30 26.54 0.02 30.54
2015-06-30 32.79 0.03 34.93
2015-03-31 9.61 0.01 10.71
2014-12-31 13.30 0.01 13.56
2014-09-30 17.05 0.00 17.83
2014-06-30 22.27 0.02 22.88
2014-03-31 25.89 0.00 26.26
2013-12-31 14.98 0.02 14.77
2013-09-30 18.81 0.00 17.56
2013-06-30 21.06 0.01 19.89
2013-03-31 22.87 0.00 21.75
2012-12-31 24.89 0.00 23.78
2012-09-30 26.73 0.00 25.18
2012-06-30 7.84 0.01 6.48
  • Mologen has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Mologen's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Mologen has less than a year of cash runway based on current free cash flow.
  • Mologen has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.2% each year.
X
Financial health checks
We assess Mologen's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Mologen has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MGNK Dividends

 What is Mologen's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Mologen dividends. Estimated to be 0% next year.
If you bought €2,000 of Mologen shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Mologen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Mologen's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MGNK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MGNK Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Mologen has not reported any payouts.
  • Unable to verify if Mologen's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Mologen's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Mologen has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Mologen's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Mologen's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Mologen afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Mologen has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MGNK Management

 What is the CEO of Mologen's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Stefan Manth
COMPENSATION €48,000
AGE 62
TENURE AS CEO 0.1 years
CEO Bio

Dr. Stefan M. Manth, M.D., Ph.D., MBA, has been Chief Executive Officer of Genelux Europe and President of Genelux Europe at Genelux Corporation since July 1, 2013. Dr. Manth served as Partner and Change Leader for Strategic Marketing of Chugai Pharmaceutical Co. Ltd. Dr. Manth served as a Senior Vice President and Head of Medical Strategy & Science Unit of Chugai Pharmaceutical Co. Ltd. Dr. Manth served as Medical Officer of Chugai. Dr. Manth has 25 years of experience in the pharmaceutical industry. Dr. Manth served as Chairman of the Board of Mucovax GmbH. Since leaving Roche in 2011, Dr. Manth served as Chairman for Mucovax Scientific and Strategic Advisory Board at Mologen AG. Dr. Manth was Vice Chairman of the Supervisory Board at Mologen AG from August 13, 2014 to March 27, 2019. Dr. Manth served as a Non Executive Director at Cardiorentis AG. Dr. Manth served as a Member of Scientific Advisory Board at Mologen Holding AG and Mologen AG. until September 30, 2012. Dr. Manth received his medical training (MD and internship) at the Freie Universitaet, Berlin and was awarded the title Dr. med. upon completion of a thesis in experimental cardiac surgery. He holds an INSEAD MBA (Fontainebleu, France).

CEO Compensation
  • Stefan's compensation has been consistent with company performance over the past year.
  • Stefan's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the Mologen management team in years:

1.9
Average Tenure
  • The average tenure for the Mologen management team is less than 2 years, this suggests a new team.
Management Team

Stefan Manth

TITLE
CEO & Member of the Executive Board
COMPENSATION
€48K
AGE
62
TENURE
0.1 yrs

Walter Miller

TITLE
CFO & Member of Executive Board
COMPENSATION
€323K
TENURE
3 yrs

Matthias Baumann

TITLE
Chief Medical Officer & Member of Executive Board
COMPENSATION
€228K
AGE
60
TENURE
1.9 yrs

Burghardt Wittig

TITLE
Co-Founder and Chairman of Scientific Advisory Board
COMPENSATION
€645K

Claudia Nickolaus

TITLE
Head of Investor Relations & Corporate Communications
Board of Directors

Oliver Krautscheid

TITLE
Chairman of the Supervisory Board
COMPENSATION
€70K
AGE
50
TENURE
4.7 yrs

Burghardt Wittig

TITLE
Co-Founder and Chairman of Scientific Advisory Board
COMPENSATION
€645K

Ulrich Granzer

TITLE
Member of Scientific Advisory Board
AGE
57

Dirk Arnold

TITLE
Member of Scientific Advisory Board

Viktor Grünwald

TITLE
Member of Scientific Advisory Board

Michael Schultz

TITLE
Member of the Supervisory Board
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Mologen's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Mologen has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MGNK News

Simply Wall St News

Mologen AG's (FRA:MGNK) Profit Outlook

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases. … With the latest financial year loss of -€19.3m and a trailing-twelve month of -€13.6m, the €26m market-cap alleviates its loss by moving closer towards its target of breakeven? … In this article, I will touch on the expectations for MGNK’s growth and when analysts expect the company to become profitable

Simply Wall St -

If You Had Bought Mologen (FRA:MGNK) Stock Five Years Ago, You'd Be Sitting On A 96% Loss, Today

Because Mologen is loss-making, we think the market is probably more focussed on revenue and revenue growth, at least for now. … When a company doesn't make profits, we'd generally expect to see good revenue growth. … Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Simply Wall St -

Does Market Volatility Impact Mologen AG's (FRA:MGNK) Share Price?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility).

Simply Wall St -

Breakeven On The Horizon For Mologen AG (FRA:MGNK)

The €19m market-cap posted a loss in its most recent financial year of -€19.3m and a latest trailing-twelve-month loss of -€13.6m shrinking the gap between loss and breakeven? … The most pressing concern for investors is MGNK’s path to profitability – when will it breakeven. … In this article, I will touch on the expectations for MGNK’s growth and when analysts expect the company to become profitable?

Simply Wall St -

What Kind Of Shareholders Own Mologen AG (FRA:MGNK)?

Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. … Mologen is a smaller company with a market capitalization of €25m, so it may still be flying under the radar of many institutional investors. … Taking a look at the our data on the ownership groups (below), it's seems that.

Simply Wall St -

Mologen AG (FRA:MGNK) Is Trading At A 49.18% Discount

How far off is Mologen AG (FRA:MGNK) from its intrinsic value? … by taking the expected future cash flows and discounting them to their present value. … Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model

Simply Wall St -

MGNK Company Info

Description

Mologen AG, a biotechnology company, develops immunotherapies for the treatment of oncology and infectious diseases. The company’s lead product is Lefitolimod, an immunotherapeutic agent, which is in Phase III study for the treatment of colorectal cancer; Phase II trial for the treatment of small lung cancer; and Phase Ib/IIa study of lefitolimod in human immunodeficiency virus-infected patients under antiretroviral therapy through collaborations with the Aarhus University Hospital in Denmark. Its lead product Lefitolimod is also under Phase I combination study with the checkpoint inhibitor Yervoy to treat advanced solid tumors in collaboration with MD Anderson Cancer Center at the University of Texas, the United States. In addition, the company is involved in the development of EnanDIM molecules, which are under pre-clinical development for cancer/anti-infective therapies; and MGN1601, a cell based therapeutic vaccine, which is has completed Phase I/II trial for the treatment of renal cancer. Mologen AG was founded in 1998 and is headquartered in Berlin, Germany.

Details
Name: Mologen AG
MGNK
Exchange: DB
Founded: 1998
€22,988,725
7,537,287
Website: http://www.mologen.com
Address: Mologen AG
Fabeckstrasse 30,
Berlin,
Berlin, 14195,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB MGNK Ordinary Shares Deutsche Boerse AG DE EUR 25. Jun 1999
XTRA MGNK Ordinary Shares XETRA Trading Platform DE EUR 25. Jun 1999
BATS-CHIXE MGND Ordinary Shares BATS 'Chi-X Europe' GB EUR 25. Jun 1999
Number of employees
Current staff
Staff numbers
51
Mologen employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 21:14
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/04/09
Last earnings filing: 2018/11/08
Last earnings reported: 2018/09/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.